Skip to main content

An Aphria worker looks out over a crop of marijuana in an undated handout image.

HO-Aphria/THE CANADIAN PRESS

In an unusual move, licensed marijuana producer Aphria Inc. is cutting the amount of cash it is offering for cannabis company Nuuvera Inc. – from $1 to 60 cents per share – as Nuuvera seeks to fully acquire its subsidiary Avanti Rx Analytics.

Leamington, Ont.-based Aphria said Tuesday it reached an agreement with Toronto-based Nuuvera to the lower the price but did not elaborate on why.

Nuuvera said in a separate release it agreed to the amendment "in order to fund" its own acquisition of the remaining 49 per cent interest of Avanti – which provides research and testing services to the cannabis industry – for an estimated $43-million.

Story continues below advertisement

The company did not explain why receiving less money from Aphria would help fund its own transaction.

"The acquisition of Avanti is an important step in the history of Nuuvera and is expected to result in synergies at the combined Nuuvera/Aphria which will enhance the value of the arrangement to shareholders of Nuuvera," said Ronald Schmeichel, Nuuvera's chairman, in a statement.

Neither company could not be immediately reached for further comment.

Nuuvera said it entered into a letter of intent to acquire the remaining interest of Avanti from a single minority shareholder. As part of the deal, Nuuvera also anticipates acquiring Avanti's facility in Brampton, Ont.

The original agreement was valued at $826-million, according to Aphria and Nuuvera's Jan. 29 release. The revised offer, with the reduced cash component and using Aphria's latest closing price of $14.06, based on 80.13 million outstanding Nuuvera shares would be valued at $447.9-million.

Under the amended deal, Aphria is offering 60 cents in cash plus 0.3546 of an Aphria share. Nuuvera noted in its release "the consideration has been reduced... provided that the cash consideration will be increased to the extent the company's unrestricted cash exceeds the revised required level."

Shares of Aphria and Nuuvera have fallen since the original deal was first announced on Jan. 29. Under the initial agreement, the licensed producer offered $1 plus 0.3546 of an Aphria share for each Nuuvera share. That would value the offer at roughly $8.50 per share, based on Aphria's 10-day volume-weighted average price for the period ended Jan. 26 of $21.15. Nuuvera's 10-day volume-weighted price for the same period was $6.51.

Story continues below advertisement

On Friday, Aphria shares closed at $14.06 on the Toronto Stock Exchange while Nuuvera shares closed at $5.56 on the TSX Venture Exchange. Based on Friday's share price, Aphria's amended offer of 60 cents in cash plus 0.3546 of a common share would be valued at $5.59 per share.

Aphria's stock was up $1.13 or 8.04 per cent to $15.19 in early afternoon trading on Tuesday, while Nuuvera was up 14 cents or 2.52 per cent to $5.70.

Aphria said Tuesday it also sought and received consent for the reduction from shareholders who had signed lock-up agreements, that together with Nuuvera shares already owned by Aphria represent approximately 65 per cent of Nuuvera's outstanding shares and over 57 per cent of the requisite minority shareholders of Nuuvera.

Aphria added that its board of directors received an opinion from its financial adviser, Cormark Securities Inc., that said as of Feb. 19 the amendment is "fair, from a financial point of view, to Aphria."

Nuuvera noted its board also obtained legal and financial advice from Canaccord Genuity Group Inc., which concluded that as of Feb. 19 that "the consideration to be received by Nuuvera shareholders is fair, from a financial point of view, to such shareholders."

Aphria said the deal is expected to close in April, on schedule.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Cannabis pro newsletter